Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Semaglutide suppresses appetite by mimicking the GLP-1 hormone, which activates receptors in the brain
Week 12+: Continued weight loss, potential dose adjustments, focus on long-term maintenance
In a statement, Wegovy's maker Novo Nordisk said it was "encouraged" by the new guidance from CMS but said it hopes to see Part D coverage expanded for "obesity medicines when used for chronic weight management." The drug maker is among those pushing for Congress to expand coverage of treatments for obesity
Refrigerate at 28 C the moment reconstitution completes
Providers should actively listen and address these issues promptly to ensure the best possible outcomes
US$ 25.41
US$ 29.45
US$ 23.54
US$ 26.00
